AB Science S.A. is a clinical-stage pharmaceutical company headquartered in Paris, France, founded in 2001. It specializes in the research, design, development, and marketing of innovative drugs targeting diseases with high unmet medical needs, particularly in oncology, inflammatory diseases, and neurological disorders. The company's lead compound, masitinib, is a highly selective tyrosine kinase inhibitor currently advanced in phase 3 clinical trials for conditions such as amyotrophic lateral sclerosis (ALS), indolent severe systemic mastocytosis, severe asthma, progressive multiple sclerosis, and metastatic castrate-resistant prostate cancer. AB Science also develops AB8939, a microtubule destabilizer for acute myeloid leukemia, and maintains a diversified pipeline with multiple late-stage programs. Notably, masitinib is already marketed in veterinary medicine as Masivet® in Europe since 2008 and Kinavet® in the USA since 2010 for canine mast cell tumors, providing recurring revenues and validating its therapeutic potential across species. Operating within the pharmaceuticals and biotechnology sector, AB Science S.A. bridges innovations in animal and human health, contributing to advancements in specialty drug manufacturing through rigorous international clinical studies and regulatory achievements.